MX342920B - Metodo para purificar polipeptidos o inmunoconjugados activos. - Google Patents

Metodo para purificar polipeptidos o inmunoconjugados activos.

Info

Publication number
MX342920B
MX342920B MX2013001044A MX2013001044A MX342920B MX 342920 B MX342920 B MX 342920B MX 2013001044 A MX2013001044 A MX 2013001044A MX 2013001044 A MX2013001044 A MX 2013001044A MX 342920 B MX342920 B MX 342920B
Authority
MX
Mexico
Prior art keywords
immunocojugates
active polypeptides
purifying active
immunoconjugate
active polypeptide
Prior art date
Application number
MX2013001044A
Other languages
English (en)
Spanish (es)
Other versions
MX2013001044A (es
Inventor
Hunter Alan
Thompson Christopher
Linke Thomas
K Wang William
Shah Ambarish
Sathish Hasige
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2013001044A publication Critical patent/MX2013001044A/es
Publication of MX342920B publication Critical patent/MX342920B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/12—Macromolecular compounds
    • B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2013001044A 2010-07-30 2011-07-27 Metodo para purificar polipeptidos o inmunoconjugados activos. MX342920B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36914810P 2010-07-30 2010-07-30
PCT/US2011/045524 WO2012015912A1 (en) 2010-07-30 2011-07-27 Method for purifying active polypeptides or immunocojugates

Publications (2)

Publication Number Publication Date
MX2013001044A MX2013001044A (es) 2013-06-05
MX342920B true MX342920B (es) 2016-10-19

Family

ID=45530485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001044A MX342920B (es) 2010-07-30 2011-07-27 Metodo para purificar polipeptidos o inmunoconjugados activos.

Country Status (16)

Country Link
US (5) US9580461B2 (enExample)
EP (3) EP3797847A1 (enExample)
JP (1) JP6061853B2 (enExample)
CN (1) CN103079666B (enExample)
BR (1) BR112013002334A2 (enExample)
CA (1) CA2806314C (enExample)
DK (1) DK3434346T3 (enExample)
ES (2) ES2678204T3 (enExample)
HU (2) HUE051702T2 (enExample)
LT (2) LT3434346T (enExample)
MX (1) MX342920B (enExample)
NO (1) NO2021030I1 (enExample)
PL (1) PL3434346T3 (enExample)
PT (1) PT3434346T (enExample)
SG (3) SG187587A1 (enExample)
WO (1) WO2012015912A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
BR112013002334A2 (pt) 2010-07-30 2016-05-24 Medimmune Llc método para purificar polipeptídeos ou imunoconjugados ativos.
CA2815342A1 (en) * 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
SG11201407809QA (en) 2012-05-31 2014-12-30 Agency Science Tech & Res Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
CN105007937B (zh) * 2012-12-20 2019-11-19 米迪缪尼有限公司 生产免疫偶联物的方法
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR101531479B1 (ko) * 2014-11-21 2015-06-26 세원셀론텍(주) 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
EP3280444B1 (en) * 2015-04-10 2024-05-08 Adimab, LLC Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
WO2018075357A1 (en) * 2016-10-17 2018-04-26 Duke University PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
WO2018187388A1 (en) * 2017-04-04 2018-10-11 Scarab Genomics, Llc Improved purification of crm 197 from bacteria
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
WO2019071150A1 (en) * 2017-10-06 2019-04-11 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
US12514927B2 (en) 2019-10-30 2026-01-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
IL295143B2 (en) 2020-02-13 2026-02-01 Hoffmann La Roche A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry
EP4175969A4 (en) * 2020-07-01 2024-07-24 Medimmune, LLC DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPY AGENT

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
JP2665827B2 (ja) 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US7355012B2 (en) * 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
WO2003051926A2 (en) * 2001-12-14 2003-06-26 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
JP2004089182A (ja) * 2002-06-24 2004-03-25 Takeda Chem Ind Ltd がんの予防・治療剤
PT1543038T (pt) * 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
DE602004027291D1 (de) * 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
US20080125363A1 (en) 2004-12-14 2008-05-29 Enzon Pharmaceuticals Inc. Polymer-Linked Pseudomonas Exotoxin Immunotoxin
ATE524489T1 (de) 2005-07-29 2011-09-15 Us Gov Health & Human Serv Mutierte pseudomonas-exotoxine mit reduzierter antigenität
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
US20110250199A1 (en) * 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
CA2737597C (en) * 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
BR112013002334A2 (pt) 2010-07-30 2016-05-24 Medimmune Llc método para purificar polipeptídeos ou imunoconjugados ativos.

Also Published As

Publication number Publication date
SG10202009967TA (en) 2020-11-27
DK3434346T3 (da) 2020-12-07
SG10201506030RA (en) 2015-09-29
US9580461B2 (en) 2017-02-28
CA2806314C (en) 2019-09-24
HUS2100027I1 (hu) 2021-07-28
ES2836447T3 (es) 2021-06-25
MX2013001044A (es) 2013-06-05
EP2613857A4 (en) 2015-01-14
EP2613857B1 (en) 2018-05-30
JP6061853B2 (ja) 2017-01-18
HUE051702T2 (hu) 2021-03-29
ES2678204T3 (es) 2018-08-09
US20180371094A1 (en) 2018-12-27
CN103079666B (zh) 2017-10-24
US20210395370A1 (en) 2021-12-23
AU2011282774B2 (en) 2016-05-26
CA2806314A1 (en) 2012-07-02
EP3434346B1 (en) 2020-09-02
LT3434346T (lt) 2020-12-28
BR112013002334A2 (pt) 2016-05-24
EP3797847A1 (en) 2021-03-31
US20200231680A1 (en) 2020-07-23
EP3434346A1 (en) 2019-01-30
US10072083B2 (en) 2018-09-11
PL3434346T3 (pl) 2021-04-06
AU2011282774A1 (en) 2013-01-31
US20170145100A1 (en) 2017-05-25
PT3434346T (pt) 2020-11-26
LTPA2021517I1 (enExample) 2021-08-25
EP2613857A1 (en) 2013-07-17
SG187587A1 (en) 2013-03-28
US20130202626A1 (en) 2013-08-08
JP2013534217A (ja) 2013-09-02
CN103079666A (zh) 2013-05-01
US11136396B2 (en) 2021-10-05
US10556955B2 (en) 2020-02-11
WO2012015912A1 (en) 2012-02-02
NO2021030I1 (no) 2021-07-15

Similar Documents

Publication Publication Date Title
BR112013002334A2 (pt) método para purificar polipeptídeos ou imunoconjugados ativos.
MX370828B (es) Métodos de purificación de polipéptidos.
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
IN2015MN00139A (enExample)
WO2013138793A3 (en) Affinity reagants for protein purification
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
PH12015502412A1 (en) Engineered phenylalanine ammonia lyase polypeptides
MX347257B (es) Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
AU2016204248A1 (en) Boron-Containing Molecules
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MA34091B1 (fr) Anticorps anti-cd40
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2012013682A3 (en) Protein purification
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
EP2992021A4 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
ZA201303834B (en) Method for purifying human granulocyte-colony stimulting factor from recombinant e. coli
HK1212995A1 (zh) 一种纯化蛋白质的方法
IN2014MN00125A (enExample)
HK1201067A1 (en) Sialic acid analogs
WO2013024267A3 (en) Stabilized compositions against ionising radiation

Legal Events

Date Code Title Description
FG Grant or registration